Fresenius Kabi Entered into a License Agreement with Formycon to Commercialize FYB202 (biosimilar, ustekinumab)
Shots:
- Formycon is eligible to receive up front & milestones upon the achievement of regulatory events with post-commercialization value to be shared equally by both companies. The proposed biosimilar is currently in the advanced clinical stage
- Fresenius Kabi will get exclusive commercialization right to FYB202, a proposed biosimilar referencing Stelara in key global markets after successful approval by respective health agencies, incl. Germany as well as parts of the MENA region and Latin America
- Formycon will be in charge of development and registration with health authorities. Fresenius Kabi will expand its product portfolio with other autoimmune disease treatment options
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon Reports P-III (VESPUCCI) Trial Results of FYB202 (biosimilar, ustekinumab) for the Treatment of Psoriasis Vulgaris
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
